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A B S T R A C TObjective: To quantify the cost differences and predictors of lost
productive time (LPT) in persons with chronic migraine (CM) and
episodic migraine (EM). Methods: The American Migraine Prevalence
and Prevention (AMPP) study is a US national longitudinal survey
of severe headache. Cost estimates were obtained via U.S. Census
income data. To elucidate the unique predictors of LPT, the optimal
distribution for modeling was determined. Zero inflation models for
LPT were predicted from sociodemographics, headache features,
characteristics and disability, medication use, and depression. The
interaction between headache status and age was the primary effect
of interest. Results: The eligible sample included 6329 persons with
EM and 374 persons with CM. Men with CM aged 45 to 54 years cost
employers nearly $200 per week more than do their EM counterparts.see front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.08.2212
est: Daniel Serrano has received grant support fro
laxoSmithKline, ENDO Pharmaceuticals, MAP Ph
he AMPP data set. Aubrey N. Manack is a full-tim
ational Headache Foundation via funding from All
ls, Novartis, OrthoMcNeil, and Merck, Inc., for da
ultant and/or received research funding from Alle
ceuticals, and Merck, Inc. Sepideh F. Varon is a fu
Pharmaceuticals, Endo Pharmaceuticals, GlaxoSm
l Headache Foundation, and the National Ins
straZeneca, Endo Pharmaceuticals, GlaxoSmithKli
dence to: Daniel Serrano, Vedanta Research, 906 E
@vedantaresearch.comLikewise, for women, costs were higher for CM, with the cost
differential between EM and CM being $90 per week. After compre-
hensive adjustment, increases in LPT with age were significantly
higher in CM than in EM (rate ratio 1.03; 95% confidence interval
1.01–1.05). When age was recoded to a decade, metric rates of LPT
increased 25% more per decade for CM than for EM (rate ratio 1.25;
95% confidence interval 1.004–1.5). Conclusions: LPT is more costly
and increases more rapidly for those with CM than for those with EM
as age increases.
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Migraine is a common, disabling headache condition that is
divided into two forms: episodic migraine (EM) and chronic
migraine (CM) [1–3]. According to population-based studies that
generally define CM by the presence of migraine in persons with
headaches on at least 15 days per month, CM has a prevalence of
0.91% to 2.2% in adults [4,5], which is far lower than the EM
prevalence of approximately 12% [6]. Data from studies aiming to
assess and compare the epidemiological profiles of CM and EM
have determined that these migraine populations are similar in
that they are on average mostly female, Caucasian, with a highbody mass index (BMI); however, those with CM are slightly older
[7,8]. In addition, several studies have demonstrated that CM
accounts for a disproportionate share of the overall disability as
well as the social and economic burden associated with migraine
[8–10].
Regarding the specific impact of migraine in the workplace,
people with CM and EM experience significant work-related
consequences [9,11]. An important marker of this impact is lost
productive time (LPT). LPT estimates the per-person hours per
week of productivity loss caused by reduced performance at work
(‘‘presenteeism’’) and absence from work (‘‘absenteeism’’) due to
disability. LPT is calculated as the sum of absenteeism andSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 1 – 3 832presenteeism weighted by the amount of time spent working in
an average week [12,13].
Recent evidence from the American Migraine Prevalence and
Prevention (AMPP) study demonstrated that among those with
migraine, increased number of headache days per month
accounted for increased LPT [9,11]. However, the differential
age-specific impact of LPT in persons with CM and EM is not
well understood. Given age variations in the prevalence between
CM and EM and the variability in disease severity, understanding
the relative impact of CM on the course of LPT across age is
essential to characterizing CM-related burden, not just to the
individual, but to society, the economy, as well as employers.
To address these issues, data from the AMPP study were
utilized to quantify the corresponding per-person cost of LPT
stratified on age and gender between persons with CM and EM. In
addition, we modeled differences in age-based fluctuations of
LPT between persons with CM and EM.Methods
Survey and Population
The AMPP study employs a longitudinal, population-based sam-
pling design whose two-phase methodology has been detailed
elsewhere [14]. Briefly, in phase 1, a self-administered screening
questionnaire was mailed to a stratified random sample of
120,000 households, selected to be representative of the US
population. Households were drawn from a 600,000-household
nationwide panel maintained by National Family Opinion, Inc., a
survey sampling firm. Of the 162,756 respondents to the screener,
30,291 persons with useable surveys reported severe headache in
their lifetime and 28,261 reported one or more severe headaches
in the preceding year. A random sample of 24,000 adults (Z18
years of age) with severe headache was selected to participate in
phase 2: a 5-year longitudinal study with annual follow-up.
In 2005, the first year of phase 2 sampling, a total of 18,500
valid returns were obtained for respondents aged 18 years or
older, and these individuals have constituted, for the most part,
the AMPP panel in every year of follow-up. In 2005, as in all years,
respondents completed a self-administered questionnaire asses-
sing variables including but not limited to demographics, medical
and psychiatric comorbidities, medication use and health care
resource utilization for headache, and headache symptoms and
characteristics, including a module designed to permit assign-
ment of International Classification of Headache Disorders 2
(ICHD-2) diagnoses [1].
Headache Classification
The headache diagnosis module within the AMPP study has a
sensitivity of 100% and a specificity of 82% for migraine diagnosis
[15] and a sensitivity of 91% and a specificity of 80% for CM
diagnosis [16]. The definitions of both EM and CM were based on
the Silberstein-Lipton criteria [17], a variation of the definition
outlined in ICHD-2R [2]. Respondents were classified as having
EM if they met ICHD-2 criteria for migraine and reported head-
ache occurring on fewer than 15 days/month on average over the
preceding 3 months. Similarly, persons with CM were identified
if they met ICHD-2 criteria for migraine but reported headaches
an average of 15 or more days/month over the preceding 3
months.
Assessment of Variables
Variables contained within the AMPP study questionnaire con-
sidered in this analysis included demographics, headachesymptoms and characteristics, acute and prophylactic medica-
tion utilization, and depression status.
Demographics included age, gender, BMI total score (calcu-
lated on the basis of the standard algorithm), average annual
household income, subdivided into five categories (o$22,500,
$22,500–$39,999, $40,000–$59,999, $60,000–$89,999, and
Z$90,000), education attainment (eight grades or less, some high
school, high school graduate or Graduate Equivalent Diploma/
General Educational Development (GED), some college or techni-
cal school, college graduate, and graduate degree), and race
(Caucasian, African-American, Asian or Pacific Islander, Amer-
ican Indian/Aleut Eskimo, Hispanic, and other). Race was dichot-
omized within this analysis to contrast Caucasians against all
other races.
Headache characteristics focused on allodynia, as measured
by the 12-item Allodynia Symptom Checklist [18], headache-
related disability as measured by the Migraine Disability Scale
(MIDAS) [19], and a composite measure of migraine-related
symptom severity (MSS). The validated 12-item Allodynia Symp-
tom Checklist may be scored in multiple ways; herein, we used
the diagnostic cutoff score of 3 or more [18]. MIDAS may also be
scored in multiple ways; herein, we used the raw score, ranging
from 0 to 270, with higher scores representing increased
headache-related disability [19]. MSS scores range from 0 to 16
and are calculated by summing responses to seven items asses-
sing ICHD-2 symptoms. These items assess unilateral pain,
pulsating pain, moderate or severe pain intensity, aggravation
of pain with physical activity (e.g., walking or climbing stairs),
nausea, photophobia, and phonophobia, measured on a 0 to 2
frequency scale where 0 indicates absence of symptoms, 1
indicates symptoms occurring less than half the time, and 2
indicates symptoms occurring half the time or more. Summing
these items and adding to it one additional item on visual aura,
with values of 0 or 2, yields the MSS score having a range from
0 to 16.
Medication utilization was assessed by two large inventories
of medication use for headache, one for acute medications and
another for prophylactic medications. Acute medication users
were identified on the basis of self-report of current use of any
nonsteroidal anti-inflamatory drug, triptan, ergotamine, barbi-
turate, or opioid. Prophylactic medication use was defined on
the basis of endorsement of a single item assessing current
preventive medication use for headache or self-report of use of
any drug classified within the AMPP study as a prophylactic
compound including depakote, neurontin, topomax, cymbalta,
effexor, elavil, pamelor, paxil, fluoxetine (Prozac), sertraline
(Zoloft), blocadren, calan, covera-HS, isoptin, corgard, inderal,
lopressor, toprol XL, procardia, tenormin, and botulinum toxin.
Depression was assessed through responses to the PRIME-MD
Patient Health Questionnaire-depression module [20], a validated
measure of current major depressive disorder based on Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition, criteria
[21]. Following PRIME-MD guidelines, a score of 10 or more was
used to define major depressive diagnosis.
Respondents were also asked about current employment
status. Response options included working for pay full or part
time, unemployed, retired, a student, a homemaker, disabled, a
volunteer, on medical or maternity leave, or ‘‘other.’’ In addition,
respondents completed the Work and Health Questionnaire
(WHQ) [12,13], a 17-item, self-administered questionnaire that
assesses usual number of hours worked/week, number of missed
workdays in the preceding 2 weeks (‘‘absenteeism’’), days at work
not feeling well and reduced work performance (‘‘presenteeism’’),
and reasons for absenteeism and presenteeism. Absenteeism and
presenteeism estimates were based on responses to six questions
and a previously validated weighting and scoring method [11–13,22].
LPT estimates were based on a weekly average self-report of hours
Fig. 1 – Model fit for count models considered.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 1 – 3 8 33absent from work (‘‘absenteeism’’) and work productivity reduction
(‘‘presenteeism’’) related to illness.
Analysis Sample
Participants eligible for this analysis were respondents to the
2005 AMPP survey meeting ICHD-2 criteria for migraine (either
EM or CM) and reporting either full- or part-time employment,
and completing the WHQ. To limit the impact of part-time and
retired persons on LPT and cost estimates, the analysis sample
was further restricted by requiring that respondents be aged 25 to
64 years, roughly corresponding to the period of peak full-time
employment.
LPT Cost Estimation
We estimated per-person average cost of LPT across demographic
strata to monetize the impact and burden of LPT. We obtained
median income estimates for demographic strata from the 2000 U.S.
Census (http://www.census.gov/hhes/income/histinc/incpertoc.html)
projections for the year 2005. These data were then merged into the
AMPP study database and served as individual-specific income
proxies based on gender, age, and race membership. Median annual
income was converted to hourly wage by first converting to weekly
income by dividing by 52 (number of weeks in a year) and then
converting to hourly by dividing this value by 40 (average hours for a
workweek). LPTwas thenmonetized by multiplying the LPT hours by
the estimated hourly wage. Given the sparseness of available
respondents within certain racial groups, monetized LPT was col-
lapsed across race and presented for gender and age only.
Monetizing LPT estimates conveys impact in a commonly
interpretable scale but does not explain what drives the LPT
estimates and subsequent costs. Therefore, to understand pre-
dictors of LPT, we examined a series of models predicting
non–cost-converted estimates of LPT.
Modeling LPT
Our main hypothesis centered around testing whether persons
with CM and EM differed in their LPT trends as a function of age
in adjusted cross-sectional analyses. This was accomplished by
predicting LPT from main effects for age and headache status
(CM vs. EM, with EM group as the reference) and the interaction
between age and headache status. Several count models were
considered as candidates for this analysis (poisson, negative
binomial, zero-inflated poisson (ZIP), and zero-inflated negative
binomial (ZINB); see Appendix 1 in Supplemental Materials found
at doi: 10.1016/j.jval.2012.08.2212 for model selection rationale).
For the purposes of model selection, model fit was evaluated
comparing model-specific predicted probabilities to observed
probabilities. Predicted values calculated within SAS’ COUNTREG
procedure did not conform to those generated from functions
given by both Hilbe [23] and Long [24]; therefore, calculations of
both link-transformed linear and inflation-weighted predicted
values used in figures were obtained from the PREDICT function
within SAS’ NLMIXED procedure [25]. Predicted values were
calculated for each model considered, and the differences
between observed and predicted values, or, discrepancy, were
plotted jointly. The model for which approximate zero discre-
pancy was achieved fastest was selected as the analysis model.
As revealed in Figure 1, plotting the discrepancy values demon-
strated that the ZINB model fit the data best. LPT was therefore
modeled by using ZINB regression models.
The ZINB model may be thought of as a piece-wise likelihood
function that fits a binomial-logistic likelihood for zero values of
LPT and a negative binomial likelihood to the entire count process
weighted by the complement of the zero-model probability (see
Hilbe [21] for full details of estimating equations). To assess thestability of the observed interaction effect, this model was exposed
to a series of covariate adjustments ordered hierarchically: Model 1 (baseline model): age, headache status, and age-
interaction. Model 2 (demographic model): Model 1 þ gender, BMI, educa-
tion level, household income, and race. Model 3 (headache characteristics model): Model 2 þmigraine
symptom severity, allodynia, and headache-related disability. Model 4 (medication use model): Model 3 þ acute medication
and preventive medication use for headache. Model 5 (depression model): Model 4 þ depression status.
We opted to fit a simple inflation model for zero values in which
we hypothesized that lower rates of missing work or reduced
productivity at work or school based on the first two items of
MIDAS would be associated with higher odds of having zero LPT.
All models were fit in SAS’ COUNTREG procedure in version 9.2
[25]. Point estimates and standard errors were obtained from the
COUNTREG procedure. Confidence intervals are not provided by
the COUNTREG procedure, and so Wald intervals were calculated.
Within the demographic model (model 2), the reference for
gender was females, BMI was fit with a linear trend, as were the
five levels of income and six education levels, while race was
dichotomized contrasting Caucasian against a reference of all
other races. Under the headache characteristics model, the MSS
score was used along with allodynia diagnosis, and MIDAS raw
disability score. Within the medication use model, acute medica-
tion use was contrasted against the nonuse of acute medications
and prophylactic medication use was contrasted against the
nonuse of prophylactic medications. Last, the depression model
included a binary depression variable defined by cutting the
Patient Health Questionnaire score at a value of 10 or more to
define subjects with moderate to severe depression.Results
2005 AMPP Survey Sample
Data were available on 18,500 respondents aged 18 years and older
surveyed in 2005 of which 6,465 met ICHD-2 criteria for migraine,
Table 1 – Effect of inclusion criteria, contrasting those included in analysis against those excluded from analysis.
Variable Levels Exclude: Include: Contrast
N¼5589, 46.4% N¼6465, 53.6%
Genderz Female N(%) 4571(81.79) 5060(78.27)
Male N(%) 1018(18.21) 1405(21.73) 1.25(1.14-1.36)
Continuous BMI Score† M(SD) 29.87(8.52) 28.76(7.42) 1.11(1.40 -0.82)
Educationz 8 grades or less N(%) 114(2.08) 22(0.34)
Some high school N(%) 411(7.49) 136(2.11) 2.58(2.41-2.76)
High school graduate or GED N(%) 1669(30.42) 1200(18.60)
Some college or technical school N(%) 2156(39.30) 2483(38.48)
College graduate (bachelor’s degree) N(%) 748(13.63) 1684(26.10)
Graduate degree N(%) 388(7.07) 927(14.37)
Incomez $22,500 N(%) 2093(37.45) 941(14.56)
$22,500-$39,999 N(%) 1208(21.61) 1218(18.84) 2.87(2.68-3.06)
$40,000-$59,999 N(%) 908(16.25) 1342(20.76)
$60,000-$89,999 N(%) 743(13.29) 1478(22.86)
$90,000þ N(%) 637(11.40) 1486(22.99)
Race: Caucasian N(%) 4765(88.72) 5594(89.20) 9.84(3)
African-American N(%) 408(7.60) 412(6.57)
Asian N(%) 28(0.52) 55(0.88)
Hispanic N(%) 170(3.17) 210(3.35)
Employmentz Full time N(%) 374(63.28) 5155(79.74)
Part time N(%) 217(36.72) 1310(20.26) 0.44(0.37-0.52)
Insurancez Insured N(%) 4378(80.01) 5656(87.69)
Uninsured N(%) 1094(19.99) 794(12.31) 0.56(0.51-0.62)
Migraine severity† M(SD) 11.45(3.70) 11.36(3.56) 0.09(-0.22-0.04)
MIDAS scorey M(SD) 15.73(28.21) 10.93(18.2) 0.69(0.66-0.73)
Allodyniaz Dxþ N(%) 3363(60.17) 3471(53.69)
Dx N(%) 2226(39.83) 2994(46.31) 0.77(0.71-0.83)
Acute medicationz Non-use N(%) 2223(39.77) 2068(31.99)
Use N(%) 3366(60.23) 4397(68.01) 1.40(1.30-1.51)
Preventive medicationz Non-use N(%) 3881(69.44) 4955(76.64)
Current use N(%) 1708(30.56) 1510(23.36) 0.69(0.64-0.75)
PHQz Depression N(%) 3911(69.98) 5371(83.08)
Depression þ N(%) 1678(30.02) 1094(16.92) 0.47(0.44-0.52)
Unemployedz Not unemployed N(%) 4480(83.68) 6465(100.00)
Unemployed N(%) 874(16.32) 0(0.00) Inestimable
Retiredz Not Retired N(%) 3894(72.73) 6429(99.44)
Retired N(%) 1460(27.27) 36(0.56) Inestimable
Disabledz Not on Disability N(%) 4022(75.12) 6424(99.37)
On Disability N(%) 1332(24.88) 41(0.63) Inestimable
BMI, body mass index; Midas, Migraine Disability Assessment; PHQ, Patient Health Questionnaire.
BOLD indicates reference group.
z Statistical test obtained from binary logistic regression, in which odds ratio indicates how contrasted groups differ in odds of event relative
to reference.
† Statistical test obtained from ANOVA, in which parameter indicates how contrasted groups differ in means of variable when residuals are
normally distributed.
z Statistical test obtained from ordered logistic regression, in which odds ratio indicates how contrasted groups differ in odds of higher
response category.
y Statistical test obtained from negative binomial regression, in which rate ratio indicates how contrasted groups differ in mean levels of
variable when residuals are negatively binomially distributed.
: Statistical test based on Pearson chi2 test of marginal proportions for nominal variables.
 Indicates effects that were statistically significant when tested at a nominal alpha level of 0.05.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 1 – 3 834were employed full or part time, were aged 25 to 64 years, and
completed the WHQ. Table 1 examines the effect of inclusion
criteria by contrasting the migraine sample meeting inclusion
criteria against the migraine sample that did not meet inclusion
criteria. Those meeting inclusion criteria were more likely to be
men, had a lower BMI, reported higher education and higher
income, were more likely to be employed full time versus part
time, were more likely to have health insurance, had less headache-related disability (lower MIDAS scores), met criteria for cutaneous
allodynia diagnosis, reported higher rates of acute medication use,
reported lower rates of preventive medication use, had lower rates
of moderate or severe depression (all significant at Po 0.0001), and
differed in racial composition (Po 0.05). Migraine cases meeting
inclusion criteria did not differ from those excluded on MSS
score (P ¼ 0.15). Because of overlap with inclusion criteria, contrasts
were inestimable for rates of unemployment, retirement, and
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 1 – 3 8 35medical disability though the data indicate that those included in
analyses were far less likely than those excluded to be in these
groups. While the presence of retirees (0.56%) or those on medical
disability (0.63%) in the analysis sample seems, at first, odd, these
cases were deemed acceptable for analysis because they also
reported being employed full or part time, were in the proper age
interval (25–64 years), and LPT data indicated existing work pro-
ductivity during the sampling period. We assumed that their
endorsement of retirement status or disability was due to either
respondent error or they were retired but working in another
occupation or receiving disability while simultaneously working in
another job.Table 2 – Sociodemographic profiles of eligible1 persons with C
Variable Levels
Continuous age†
Genderz Female
Male
Continuous BMI score†
Educationz 8 grades or less
Some high school
High school graduate or GED
Some college or technical school
College graduate (bachelor’s degree)
Graduate degree
Incomez $22,500
$22,500-$39,999
$40,000-$59,999
$60,000-$89,999
$90,000þ
Race: Caucasian
African-American
Asian
Hispanic
Employmentz Full-time
Part-time
Insurancez Insured
Not insured
Migraine Severity (MSS)†
MIDAS scorey
Allodyniaz Dx þ
Dx 
Acute medicationz Non-use
Use
Preventive medicationz Non-use
Current use
PHQz Depression 
Depression þ
Lost productivityy
CM, chronic migraine; EM, episodic migraine; BMI, body mass inde
Questionnaire.
BOLD indicates reference group for logistic regressions.
1 Working full or part time, completed Work and Health Questionnaire,
z Statistical test obtained from binary logistic regression, in which odds
to reference.
† Statistical test obtained from ANOVA, in which parameter indicates ho
normally distributed.
z Statistical test obtained from ordered logistic regression, in which o
response category.
y Statistical test obtained from negative binomial regression, in which
variable when residuals are negatively binomially distributed.
: Statistical test based on Pearson chi2 test of marginal proportions forTable 2 provides a statistical summary of the sociodemographic
features of the CM and EM samples eligible for analysis. Those with
CM and EM were similar across age, gender, and BMI, with a mean
age of 44 years, approximately 80% of each group being women,
and BMI scores differing by only 0.25 units. However, persons with
CM were more likely to have a lower household income, lower
education, be Caucasian or African-American, be working part
time, not have health insurance, greater headache-related disabil-
ity, meet criteria for an allodynia diagnosis, be taking acute or
prophylactic medications for headache, meet criteria for major
depression, have higher LPT (all significant at Po 0.0001), and have
greater MSS score (Po 0.001) when compared with EM cases.M and EM.
EM CM Significance
N¼6297, 94.4% N¼373, 5.6%
M(SD) 44.08(9.65) 44.48(9.77) 0.443
N(%) 4932(78.32) 295(79.09)
N(%) 1365(21.68) 78(20.91) o.0001
M(SD) 28.73(7.42) 28.98(7.33) 0.532
N(%) 20(0.32) 5(1.36) o.0001
N(%) 142(2.27) 7(1.90)
N(%) 1164(18.64) 80(21.74)
N(%) 2396(38.37) 143(38.86)
N(%) 1616(25.88) 96(26.09)
N(%) 907(14.52) 37(10.05)
N(%) 954(15.15) 56(15.01) o.0001
N(%) 1185(18.82) 72(19.30)
N(%) 1313(20.85) 72(19.30)
N(%) 1410(22.39) 94(25.20)
N(%) 1435(22.79) 79(21.18)
N(%) 5429(88.85) 339(93.91) o.0001
N(%) 422(6.91) 10(2.77)
N(%) 56(0.92) 0(0.00)
N(%) 203(3.32) 12(3.32)
N(%) 4889(79.70) 280(78.21)
N(%) 1245(20.30) 78(21.79) o.0001
N(%) 5472(87.62) 316(85.87)
N(%) 773(12.38) 52(14.13) o.0001
M(SD) 11.32(3.58) 12.03(3.4) o.001
M(SD) 9.14(13.46) 42.53(43.1) o.0001
N(%) 3366(53.45) 219(58.71)
N(%) 2931(46.55) 154(41.29) o.0001
N(%) 2030(32.24) 115(30.83)
N(%) 4267(67.76) 258(69.17) o.0001
N(%) 4874(77.40) 236(63.27)
N(%) 1423(22.60) 137(36.73) o.0001
N(%) 5279(83.83) 263(70.51)
N(%) 1018(16.17) 110(29.49) o.0001
M(SD) 3.58(8.81) 8.4(17.51) o.0001
x; MIDAS, Migraine Disability Assessment; PHQ, Patient Health
25-64 years.
ratio indicates how contrasted groups differ in odds of event relative
w contrasted groups differ in means of variable when residuals are
dds ratio indicates how contrasted groups differ in odds of higher
rate ratio indicates how contrasted groups differ in mean levels of
nominal variables.
Table 4 – Unadjusted (model 1) and fully adjusted models2
for LPT.
Predictive factors RR (95% CI)
Model 1 Model 2
Gender 1.28 (1.15–1.43)
BMI 1.01 (1.01–1.02)
Education 0.91 (0.87–0.95)
Income 0.98 (0.95–1.02)
Race 1.14 (1.05–1.23)
Migraine severity (MSS) 1.03 (1.02–1.04)*
MIDAS 1.02 (1.01–1.02)
Allodynia 1.07 (0.97–1.18)
Acute medication use 1.13 (1.02–1.24)
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The national median hourly wage for women was noticeably
lower than that for men, as presented in Table 3. Although within
each gender, median hourly wage appeared to follow a quadratic
trend, increasing at first, stabilizing in midlife, and then decreas-
ing as subjects approach retirement. Across age and gender
groups in those employed full or part time, persons with CM
demonstrated higher costs associated with LPT than did persons
with EM. Men with CM aged 45 to 54 years had the highest
estimated LPT cost at $276.93 per person per week compared
with $80.08 per person per week for men of the same age with
EM. The same was true for women, with those having CM aged 45
to 54 years having the highest estimated LPT cost, with a $136.87
per person per week value compared with $46.93 per person per
week for women of the same age suffering from EM.Prophylactic medication
use
1.29 (1.16–1.44)
Depression 1.99 (1.78–2.23)
Age 1 (0.99–1) 1 (0.99–1)
Headache status (CM vs.
EM)
0.65 (0.27–1.55) 0.25 (0.1–0.61)
Age  Headache status
interaction
1.03 (1.01–1.05)* 1.03 (1.01–1.05)
 Gender (binary, reference ¼ female), BMI was the raw score,
education had six levels and was modeled as a trend, income
had five levels and was modeled as a trend, race (binary,
Caucasian reference ¼ other races).
 Migraine severity was a composite obtained from summing the
seven items in the AMPP migraine symptom module, MIDAS was
based on the raw disability score, allodynia (binary, reference ¼
no allodynia) was defined by using the diagnostic score from the
ASC-12 (score of 2 or more).
 Acute medication use (binary, reference ¼ no acute medication
use), prophylactic medication use (binary, based on self-report of
use of preventive compounds, or report of use of any specific
compound within the prophylaxis module in the AMPP study,
reference ¼ nonuse).
 Age based on self-report with raw value modeled as trend,
headache status (binary, CM, reference ¼ EM), interaction
between age and headache status assessed difference in LPT
between CM and EM at varying levels of age.
AMPP, American Migraine Prevalence and Prevention; ASC-12, 12-Models for LPT
Table 4 contains the unadjusted and adjusted results from the
ZINB models for LPT. The effect of interest was the interaction
between headache status (EM vs. CM) and age. In Table 4, model 1
presents the unadjusted interaction effect, while model 2 (origi-
nal model 5) presents the final interaction effect adjusted for the
full covariate set. Models 2 to 4 are not presented because results
did not differ across models, but are available on request. The
results of the inflation component model (the component pre-
dicting the absence of LPT) are not presented for models 1 and 2,
though in every case the headache-related disability item
(MIDAS) effects had the expected significant inverse association
with the odds of no LPT. Throughout this section, the main
effects constituent of significant interactions are not interpreted.
This is because in the presence of a significant interaction
constituent main effects are not uniquely defined. Therefore,
though in some of the models presented for LPT the constituent
main effects are significant, the interaction is always significant,
thus obviating the interpretation of the main effect.
In model 1 of Table 4, the age and headache status main
effects were not statistically significant; however, the rate ratio
(RR) for the interaction between age and headache status was
significant (RR 1.03; 95% confidence interval [CI] 1.01–1.05),
indicating that for every year increase in age, LPT will be 3%
greater for CM than for EM. While at first this appears to be a
relatively modest effect, one must consider that the difference inTable 3 – Comparison of cost ($/week) in LPT between CM
and EM.
Gender Age group
(years)
Hourly
wage
LPT ($/week)
CM EM
Females 25–34 $10.93/hr $61.52 $45.46
35–44 $11.97/hr $90.71 $42.84
45–54 $11.70/hr $136.87 $46.93
55–64 $9.96/hr $101.44 $33.91
Males 25–34 $14.28/hr $87.06 $53.71
35–44 $18.62/hr $208.54 $87.46
45–54 $18.01/hr $276.93 $80.08
55–64 $16.21/hr $183.15 $63.69
Wage estimates obtained from 2000 U.S. Census projections for
2005: http://www.census.gov/hhes/income/histinc/incpertoc.html.
CM, chronic migraine; EM, episodic migraine; LPT, lost productive
time.
item Allodynia Symptom Checklist; BMI, body mass index; CI,
confidence interval; CM, chronic migraine; EM, episodic migraine;
LPT, lost productive time; MIDAS, Migraine Disability Assessment
Scale; RR, rate ratio.
* Indicates effects that were statistically significant when tested at
a nominal alpha level of 0.05.
2 Models were zero-inflated negative binomial (ZINB) regression
models.LPT rates between CM and EM is cumulative as age increases.
Therefore, as demonstrated in Figure 2, across levels of age this
has a dramatic impact on LPT, with CM-specific LPT increasing
rapidly as age increases and EM displaying a slight decrease in
LPT as age increases. Moreover, the decade-equivalent estimate
(obtained by coding LPT into decade bins and refitting the model)
revealed that for every decade increase in age, LPT rates
increased 25% more for CM than for EM (RR 1.25; 95% CI
1.004–1.5. (Note that the lower limit of this interval is close to
the boundary of significance. Although the effect is significant, it
may not be the most robust estimate of the decade effect. To
avoid ambiguity about the significance of this effect, we report
the lower bound of the interval with three decimals.)
Fig. 2 – Average predicted LPT (lost hours/week) by CM and
EM across age. CM, chronic migraine; EM, episodic
migraine; LPT, lost productive time.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 1 – 3 8 37The magnitude of the interaction did not vary across adjusted
models, and therefore, the effect in the fully adjusted model is
the only additional effect discussed here. The interaction was
robust to comprehensive adjustment (RR 1.03; 95% CI 1.01–1.05)
even though certain covariates, such as depression (RR 1.99; 95%
CI 1.78–2.23), significantly and strongly predicted LPT as well.Discussion
Previous research has established that migraine is strongly
associated with LPT and although absenteeism is an important
contributor, the majority of LPT is linked to reduced performance
while at work or presenteeism [11,12]. In addition, increased
headache days per month and greater pain intensity are inde-
pendently associated with elevated LPT among those who work
for pay [11,12,22]. The findings of this study support the existing
published literature showing that CM is more disabling than EM
in terms of LPT across the age range of 25 to 64 years among
those who work for pay. When LPT was monetized, costs were
higher for CM than for EM at every age and for both men and
women. Men and women aged 45 to 54 years with CM reported
the highest LPT at $276.93 and $136.87 per person per week,
respectively.
In some ways, this cost finding is a bit counterintuitive. We
know women have higher migraine-related disability in the
population than do men [4], and would therefore expect higher
LPT in women. This logic could be extended in a manner leading
to the conclusion that costs should therefore be higher as well.
However, we do not see this in our data. There are two factors
contributing to this unexpected result. The first factor is a
consequence of the national median income being higher, on
average, for men than for women. The second factor contributing
to the higher cost of LPT among men is that men have higher LPT.
In aggregate, LPT is higher in men by only about one quarter of an
hour (women ¼ 3.79 and men ¼ 4.03). But across the strata for
which costs were calculated, LPT differs in some cases by nearly 3
hours within the CM sample, with men aged 35 to 44 years having
2.7 LPT hours more than do women in the same age group. Onepotential cause of this difference in LPT is related to the fact that
in our sample women are more likely than men to work part time.
Whereas 91.7% of the men worked full time, 76.3% of the women
did so, and while 8.3% of the men worked part time, 23.7% of the
women did so. Thus, women are more likely to work less than
men, reducing opportunities for LPT by minimizing workdays on
which headache can interfere with productivity, thereby reducing
LPT estimates. Thus, when we observe lower costs for women,
both lower census median income and reduced work hours
associated with part-time employment contribute.
There are additional important factors that should be con-
sidered while interpreting these study results. These analyses
examine the influence of age in 2005 as a predictor of LPT in 2005.
Annual LPT data to augment the understanding of how differ-
ences in LPT between CM and EM develop over time within
respondents are not available in the AMPP study. It is tempting to
interpret analyses and interaction plots as reflecting within-
subject effects. All analyses, however, were cross sectional, and
the headache status and age effects were group-level effects. At
most, the interaction serves as a proxy for what one might expect
within subjects but remains exclusively a difference in headache
status groups as LPT fluctuates across age values. It is of interest
to elucidate how the development of LPT over time differs
between CM and EM, and it will likely look similar to these
analyses, but we defer that endeavor to future work.
It is also important to note that the definition of LPT provided by
the WHQ does not differentiate between the myriad factors con-
tributing to LPT. Thus, what we are examining in this article is the
differences between EM and CM in LPT, not the difference between
LPT attributable to EM compared with LPT attributable to CM. Thus,
the elevated LPT in CM than in EM, and how this difference expands
as age increases, may reflect both the increased disease severity in
CM compared with EM and the increased rates of comorbidities in
CM compared with EM. Because we cannot differentiate between
the comorbidity contribution and the headache-disease contribu-
tion, our findings reflect the difference in the combined impact on
productivity between EM and CM.
Another limitation relates to the effect of inclusion criteria. A
majority of the differences observed between the inclusion and
exclusion groups are logical consequences of the inclusion
criteria. For example, one would expect higher education, house-
hold income, greater likelihood of having health insurance, and a
higher preponderance of the male gender among adults working
full or part time. Taken together, these findings suggest that the
segment of the EM and CM population included in analysis,
composed of adults aged 25 to 64 years working full or part time,
is far less impaired and disabled than their excluded counter-
parts. Consequently, the LPT and associated costs from under-
employment and unemployment are not represented by these
findings. Within this group LPT, at least as it relates to absentee-
ism, is 100% of full-time productivity. Deleterious consequences
associated with this departure from the labor force are not
limited to those suffering from migraine; there are substantial
costs incurred by employers losing the productivity and contribu-
tions of labor force members incapacitated and disabled by
migraine. It is possible that the elevated disability associated
with CM may lead to higher proportions of the CM population
leaving the labor force altogether, resulting in compounded costs
to the individual, family, and society. Recent publications have
demonstrated that underemployment and unemployment are
directly associated with migraine headache-days [26]; thus, costs
may be substantially underestimated within the CM population.
This is analogous to the bias of labor market assessments of
joblessness where rates are attenuated by those who are jobless
but have left the labor force and cease looking for work. Here, we
cannot validly quantify hours of LPT among those no longer
producing, though loss of productivity is highest in such
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cannot generalize our data to that segment of the CM population
who are not employed when our productivity outcome requires
employment in order to be defined. But this does not have
implications for the validity of our conclusions as they relate to
the segment of the population to whom we are generalizing: those
who are employed and who experience losses in productivity.
Last, the method of estimation of LPT costs must be considered
to be a conservative estimate, as, in the absence of individual income
data, individual income was estimated via U.S. Census median
income data for the year of data collection (2005). This method is
not considered an infallible estimator of individual-level socioeco-
nomic status data; however, literature exists supporting this work
when, as is the case with the AMPP study, samples are constructed
to replicate U.S. Census tract strata composition and income esti-
mates are obtained from the same year as that of sampling [27].
In the absence of individual-level income, this seemed like the
best available option, but may provide a conservative estimate
of costs.
Given the pressure of increasing health care costs, developing an
understanding of the monetized impact of LPT related to migraine
can help health care professionals, researchers, and headache
advocacy groups develop and promote programs that reduce the
individual and societal burden of migraine. To reduce work and
economic consequences associated with migraine, optimal migraine
treatment paradigms should be developed and include effective
acute and prophylactic pharmacologic treatments as well as empiri-
cally supported nonpharmacologic therapies. Appropriate diagnosis
is the initial step toward creating an optimal treatment paradigm;
therefore, it is important to develop programs that increase aware-
ness of migraine both within the general and health care popula-
tions. Furthermore, because CM is the migraine subtype with the
highest LPT costs and because previous research has shown that
only 20% of those with CM receive a correct diagnosis [28],
the impact of increasing rates of proper diagnosis among those
with CM may produce the greatest reduction in LPT and its
associated costs.Acknowledgment
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